A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells-Reference-Cited by-同舟云学术

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

Published:2017-07-13 Issue:10 Volume:6 Page:e1349589
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

David Justin M.¹,Dominguez Charli¹,McCampbell Kristen K.¹,Gulley James L.²,Schlom Jeffrey¹,Palena Claudia¹

Affiliation:

1. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1349589

Reference59 articles.

1. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

4. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

5. PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and future perspectives for the use of temozolomide in the treatment of SCLC;Cancer Treatment Reviews;2024-09

2. Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma;Cancers;2024-08-31

3. Therapeutic targeting of TGF‐β in lung cancer;The FEBS Journal;2024-07-31

4. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study;Clinical and Translational Science;2024-06

5. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison;Molecular Cancer;2024-04-16